Compare ECO & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECO | NEO |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2023 | 2008 |
| Metric | ECO | NEO |
|---|---|---|
| Price | $76.15 | $17.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $42.00 | $13.38 |
| AVG Volume (30 Days) | 483.2K | ★ 1.5M |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | ★ 6.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.07 | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | $18.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.74 | $7.07 |
| 52 Week High | $72.75 | $19.76 |
| Indicator | ECO | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 71.01 | 58.79 |
| Support Level | $48.27 | $15.72 |
| Resistance Level | N/A | $19.76 |
| Average True Range (ATR) | 1.95 | 0.84 |
| MACD | 0.45 | -0.09 |
| Stochastic Oscillator | 96.37 | 36.90 |
Okeanis Eco Tankers Corp is an international owner and operator of a fleet of tanker vessels used for the transportation of crude oil. Its fleet consists of modern Suezmax and VLCC tankers that are designed in accordance with eco-efficiency standards, including features such as reduced fuel consumption, exhaust gas cleaning systems, and ballast water treatment systems. All of the company's revenue is derived from a single segment, the crude oil tanker segment. Geographically, the maximum revenue is generated from Europe, and the rest from Asia, North America, and South America.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.